Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2006 | Original article

Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using⁶⁸Ga-DOTATOC PET and comparison with¹⁸F-FDG PET

Authors: Antonia Dimitrakopoulou-Strauss, Vassilios Georgoulias, Michael Eisenhut, Felix Herth, Sophia Koukouraki, Helmut R. Mäcke, Uwe Haberkorn, Ludwig G. Strauss

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2006

Abstract

Purpose

Dynamic PET studies with⁶⁸Ga-DOTATOC were performed in patients with non-small cell lung cancer (NSCLC) to assess the somatostatin receptor 2 (SSTR2) expression. Furthermore, dynamic¹⁸F-fluorodeoxyglucose (FDG) studies were performed in the same patients to compare the SSTR2 expression with the tumour viability.

Methods

The study population comprised nine patients, examined with both tracers on two different days within 1 week. Standardised uptake values (SUVs) were calculated and a two-tissue compartment model was applied to the data. Furthermore, a non-compartment model based on the fractal dimension (FD) was applied to the data.

Results

The DOTATOC uptake was generally lower than the FDG uptake. Moderately enhanced DOTATOC uptake was noted in seven of the nine tumours. All kinetic parameters exceptk ₄ were lower for DOTATOC than for FDG. The mean SUV was 2.018 for DOTATOC, in comparison to 5.683 for FDG. In particular,k ₃ was highly variable for DOTATOC and showed an overlap with the normal lung tissue. The fractional blood volumeV _B was relatively low for both tracers, not exceeding 0.3. The highest significant logarithmic correlation was found for the FD of the two tracers (r=0.764,p=0.017). The logarithmic correlation for SUVs was also significant (r=0.646,p=0.060), as was that forV _B (r=0.629,p=0.069). In contrast, none of the eight metastases which were positive on FDG PET showed any DOTATOC uptake.

Conclusion

The results demonstrated moderate⁶⁸Ga-DOTATOC uptake in primary NSCLC but did not provide any evidence for SSTR2 expression in metastases. This may be caused by loss of the gene expression in metastases as compared with the primary tumours.

Mena E, Camacho V, Estorch M, Fuertes J, Flotats A, Carrió I.^99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1399–1404CrossRefPubMed

Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, et al. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 2003;22:1141–1146PubMed

Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996;17:302–310PubMedCrossRef

Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;7:1974–1981CrossRef

Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–648PubMed

Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–1823PubMed

Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform 1998;23:207–214

Miyazawa H, Osmont A, Petit-Taboue MC, Tillet I, Travere JM, Young AR, et al. Determination of¹⁸F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 1993;50:263–272CrossRefPubMed

Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, editors. The metabolism of the human brain studied with positron emission tomography. New York: Raven Press; 1983; p.123–148

10.

Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med 1991;32:1432–1438PubMed

11.

Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Mikolajczyk K, Lehnert T, Bernd L, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003;2:306–313

12.

Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of (¹⁸F)-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413–1423CrossRefPubMed

13.

Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 1999;213:530–536PubMed

14.

Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR 1 and SSTR 2, in human lung cancer cell lines. Life Sci 1994;55:1797–1806CrossRefPubMed

15.

Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog^99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232–1238CrossRefPubMed

16.

Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al The utility of^99mTc depreotide compared with F-18-fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494–501CrossRefPubMed

17.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al Characterization of ⁶⁸Ga-DOTA-D-Phe¹-Tyr³-octreotide (DOTA-TOC) kinetics in patients with meningiomas. J Nucl Med 2005;46:763–769PubMed

18.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Pharmacokinetic studies of ⁶⁸Ga-DOTATOC PET in patients with metastatic neuroendocrine tumours planned for ⁹⁰Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006 Jan 17:1–7 [Epub ahead of print]. DOI 10.1007/s00259-005-0006-1

19.

Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-(¹⁸F)-fluoro-L-dopa with ¹⁸F-FDG and ¹⁵O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248–256PubMed

Title: Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET
Authors: Antonia Dimitrakopoulou-Strauss
Vassilios Georgoulias
Michael Eisenhut
Felix Herth
Sophia Koukouraki
Helmut R. Mäcke
Uwe Haberkorn
Ludwig G. Strauss
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0063-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using⁶⁸Ga-DOTATOC PET and comparison with¹⁸F-FDG PET

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2006

The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment

Pivotal role of nanotechnologies and biotechnologies for molecular imaging and therapy

Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy

Loss of neuronal integrity: a cause of hypometabolism in patients with traumatic brain injury without MRI abnormality in the chronic stage

Bilateral adrenal metastases from malignant melanoma: concordant findings on 18F-FDG and 18F-FDOPA PET

Submillimetre spatial resolution is feasible in positron emission tomography